News

The committee recommended approval for the company’s lesinurad 200 mg tablets, in combination with a xanthine oxidase inhibitor (XOI), for the adjunctive treatment of of hyperuricaemia in adults

GSK’s global HIV business, ViiV Healthcare, has signed two separate transactions, which are expected to complete independently during the first half of next year. The deals are subject

The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, which are known oncogenic drivers. The study will also

Both of these diseases are ultra-rare, with prevalences in the United States believed to be approximately 3,000 and 1,000-1,500 patients, respectively. Catalyst CEO Patrick McEnany said: "The completion

Founding partners participating in the program include: argenx, Crystal Bioscience and Sevion Therapeutics. The program combines Tetragenetics’ unique and proprietary antigen production capabilities with each partner’s novel antibody

Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for

Shkreli is alleged of misappropriating money from two hedge funds he established and made material misrepresentations to investors among other widespread misconduct. Shkreli earlier faced criticism for drastically

Acerta Pharma has operations in Oss, the Netherlands and several US sites. The US headquarters is in Redwood City, California. The deal gives AstraZeneca access to Acerta’s lead

Filgotinib is a JAK1 inhibitor discovered and developed by Galapagos using its target and drug discovery technology platform. It has been developed to treat rheumatoid arthritis (RA) and